Adding a clot-dissolving drug during stroke treatment did not improve outcomes

The BRETIS-TNK2 trial suggests that intra-arterial tenecteplase during endovascular treatment did not improve 90-day functional outcomes.

The BRETIS-TNK2 trial suggests that adding intra-arterial tenecteplase during endovascular treatment (EVT) did not improve 90-day functional outcomes. This study looked at patients with large-vessel occlusion eligible for EVT within 24 hours of symptom onset.

Researchers used a phase 3, randomised, adaptive-enrichment, open-label, blinded-endpoint multicentre study. They randomly assigned 380 patients in a 1:1 ratio to two groups. One group received tenecteplase during EVT and the control group received EVT alone.

Endovascular treatment (EVT) is a procedure used for patients with large-vessel occlusion. Intra-arterial tenecteplase may increase first-pass recanalization and dissolve microcirculatory thrombi. Favorable functional outcome was the primary endpoint.

In the tenecteplase group, 192 patients were randomised and 190 had primary outcome data. Favorable 90-day functional outcomes, measured by a modified Rankin Scale of 0-2, occurred in 40.0% of the tenecteplase group. In the control group, 188 patients were randomised and 186 had primary outcome data. Favorable outcomes occurred in 46.8% of the control group.

The unadjusted odds ratio was 0.76, with a 95% confidence interval of [0.50-1.14] and a P value of 0.19. The efficacy and safety of this strategy remain uncertain.

Key facts

  • Favorable 90-day functional outcomes occurred in 40.0% of the tenecteplase group.
  • Favorable 90-day functional outcomes occurred in 46.8% of the control group.
  • The study involved 380 randomised patients.

All sections

Edition